183 related articles for article (PubMed ID: 32796292)
1. Vaginal laser treatment of genitourinary syndrome of menopause: does the evidence support the FDA safety communication?
Guo JZ; Souders C; McClelland L; Anger JT; Scott VCS; Eilber KS; Ackerman AL
Menopause; 2020 Oct; 27(10):1177-1184. PubMed ID: 32796292
[TBL] [Abstract][Full Text] [Related]
2. Lasers and energy-based devices marketed for vaginal rejuvenation: A cross-sectional analysis of the MAUDE database.
Ahluwalia J; Avram MM; Ortiz AE
Lasers Surg Med; 2019 Oct; 51(8):671-677. PubMed ID: 30924953
[TBL] [Abstract][Full Text] [Related]
3. Vaginal energy-based devices: characterization of adverse events based on the last decade of MAUDE safety reports.
Wallace SL; Sokol ER; Enemchukwu EA
Menopause; 2020 Sep; 28(2):135-141. PubMed ID: 33003133
[TBL] [Abstract][Full Text] [Related]
4. CO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-Analysis.
Filippini M; Porcari I; Ruffolo AF; Casiraghi A; Farinelli M; Uccella S; Franchi M; Candiani M; Salvatore S
J Sex Med; 2022 Mar; 19(3):452-470. PubMed ID: 35101378
[TBL] [Abstract][Full Text] [Related]
5. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
6. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review.
Mension E; Alonso I; Tortajada M; Matas I; Gómez S; Ribera L; Anglès S; Castelo-Branco C
Maturitas; 2022 Feb; 156():37-59. PubMed ID: 34217581
[TBL] [Abstract][Full Text] [Related]
7. The Fractional CO
Li J; Li H; Zhou Y; Xie M; Miao Y; Wang L; Zhao Y; Ying T; Hu Y; Chen Y; Chen Y; Sun X; Wang J
Lasers Surg Med; 2021 Jul; 53(5):647-653. PubMed ID: 33211334
[TBL] [Abstract][Full Text] [Related]
8. Rationale and design for fractional microablative CO
Flint R; Cardozo L; Grigoriadis T; Rantell A; Pitsouni E; Athanasiou S
Climacteric; 2019 Jun; 22(3):307-311. PubMed ID: 30676818
[TBL] [Abstract][Full Text] [Related]
9. The Impact of Vaginal Laser Treatment for Genitourinary Syndrome of Menopause in Breast Cancer Survivors: A Systematic Review and Meta-analysis.
Jha S; Wyld L; Krishnaswamy PH
Clin Breast Cancer; 2019 Aug; 19(4):e556-e562. PubMed ID: 31227415
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Severity of Genitourinary Syndrome of Menopause Symptoms After Carbon Dioxide Laser vs Vaginal Estrogen Therapy: A Systematic Review and Meta-analysis.
Jang YC; Leung CY; Huang HL
JAMA Netw Open; 2022 Sep; 5(9):e2232563. PubMed ID: 36129710
[TBL] [Abstract][Full Text] [Related]
11. Update: The Clinical Role of Vaginal Lasers for the Treatment of the Genitourinary Syndrome of Menopause.
Mounir DM; Hernandez N; Gonzalez RR
Urology; 2021 May; 151():2-7. PubMed ID: 32966821
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients.
Li B; Duan H; Chang Y; Wang S
Pharmacol Res; 2021 Feb; 164():105360. PubMed ID: 33307219
[TBL] [Abstract][Full Text] [Related]
13. Laser treatment for genitourinary syndrome of menopause: Scientific Impact Paper No. 72 (July 2022): Scientific Impact Paper No. 72 (July 2022).
Phillips C; Hillard T; Salvatore S; Cardozo L; Toozs-Hobson P;
BJOG; 2022 Nov; 129(12):e89-e94. PubMed ID: 35892242
[TBL] [Abstract][Full Text] [Related]
14. Use of a vaginal CO
Mejia-Gomez J; Bouteaud J; Philippopoulos E; Wolfman W; Brezden-Masley C
Climacteric; 2022 Jun; 25(3):228-234. PubMed ID: 34694948
[TBL] [Abstract][Full Text] [Related]
15. Vaginal laser therapy for GSM/VVA: where we stand now - a review by the EUGA Working Group on Laser.
Salvatore S; Ruffolo AF; Phillips C; Athanasiou S; Cardozo L; Serati M;
Climacteric; 2023 Aug; 26(4):336-352. PubMed ID: 37395104
[TBL] [Abstract][Full Text] [Related]
16. The Er:YAG vaginal laser for management of women with genitourinary syndrome of menopause (GSM).
Lin KL; Chou SH; Loo ZX; Liu YY; Cheng JC; Long CY
Lasers Med Sci; 2022 Jun; 37(4):2203-2208. PubMed ID: 34988731
[TBL] [Abstract][Full Text] [Related]
17. Understanding a decade of safety reporting for sacral neuromodulation in the Food and Drug Administration Manufacturer and User Facility Device Experience database.
Carlton CE; Souders CP; Chertack NA; Goueli RS; Lemack GE; Anger JT; McClelland L; Carmel ME
Neurourol Urodyn; 2023 Nov; 42(8):1655-1667. PubMed ID: 37497812
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Laser Therapy for the Treatment of Genitourinary Syndrome of Menopause: A Protocol for Systematic Review and Meta-Analysis of Clinical Trials.
Pessoa LLMN; Sarmento ACA; Medeiros KS; Costa APF; Gonçalves AK; Cobucci RN
Front Reprod Health; 2021; 3():772690. PubMed ID: 36304041
[TBL] [Abstract][Full Text] [Related]
19. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity.
Shobeiri SA; Kerkhof MH; Minassian VA; Bazi T;
Int Urogynecol J; 2019 Mar; 30(3):371-376. PubMed ID: 30523374
[TBL] [Abstract][Full Text] [Related]
20. Genitourinary Syndrome of Menopause.
Marino JM
J Midwifery Womens Health; 2021 Nov; 66(6):729-739. PubMed ID: 34464022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
